Escitalopram in the treatment of major depressive disorder in primary-care settings: an open-label trial

2008 ◽  
Vol 25 (12) ◽  
pp. E173-E181 ◽  
Author(s):  
Pratap Chokka ◽  
Mark Legault
Keyword(s):  
Primary Care ◽  
Major Depressive Disorder ◽  
Depressive Disorder ◽  
Open Label ◽  
Major Depressive ◽  
Primary Care Settings ◽  
Open Label Trial

A randomized open-label trial of paroxetine versus paroxetine plus sulpiride in the treatment of major depressive disorder

2005 ◽  
Vol 20 (3) ◽  
pp. A16
Author(s):  
Hiroyuki Uchida ◽  
Hiroyoshi Takeuchi ◽  
Kensuke Nomura ◽  
Takefumi Suzuki ◽  
Koichiro Watanabe ◽  
...  
Keyword(s):  
Major Depressive Disorder ◽  
Depressive Disorder ◽  
Open Label ◽  
Major Depressive ◽  
Open Label Trial

scholarly journals Prevalence and factors associated with major depressive disorder among adolescents attending a primary care facility in Kampala, Uganda

2019 ◽  
Vol 50 (1) ◽  
pp. 30-36
Author(s):  
Leticia Kyohangirwe ◽  
Elialilia Okello ◽  
Justine D Namuli ◽  
Grace Ndeezi ◽  
Eugene Kinyanda
Keyword(s):  
Primary Care ◽  
Major Depressive Disorder ◽  
Depressive Disorder ◽  
Care Facility ◽  
Sub Saharan Africa ◽  
Major Depressive ◽  
Primary Care Facility ◽  
Factors Associated ◽  
Primary Care Settings ◽  
Physical Neglect

Information on major depressive disorder (MDD) in primary care settings in sub-Saharan Africa is limited, yet this is required to improve service development. We explored prevalence and factors associated with MDD among adolescents attending a primary care facility in urban Uganda. At Naguru Teenage Information and Health Centre, 281 adolescents were assessed for MDD using the Mini-International Neuropsychiatric Interview for Children and Adolescents (MINI-Kid). Prevalence and risk factors were determined using frequencies and regressions, respectively. The prevalence of adolescent MDD was 18.2 %. Vulnerability factors were orphanhood, childhood trauma (particularly emotional abuse and physical neglect) while social support was protective. Considerable burden of clinically significant depression exists in primary care settings in Uganda; this may well contribute to a poor quality of life.

Zuranolone in Major Depressive Disorder: Interim Safety Results From a Phase 3, Open-Label, Longitudinal Study

2021 ◽  
Vol 89 (9) ◽  
pp. S161
Author(s):  
Andrew Cutler ◽  
Scott T. Aaronson ◽  
Gregory W. Mattingly ◽  
Samuel T. Wilkinson ◽  
Robert Lasser ◽  
...  
Keyword(s):  
Major Depressive Disorder ◽  
Longitudinal Study ◽  
Depressive Disorder ◽  
Open Label ◽  
Major Depressive ◽  
Phase 3
Sign in / Sign up

Export Citation Format

Share Document